1. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer
- Author
-
Ege Devries, Phb Willemse, A. G. Nanninga, and J. Boonstra
- Subjects
Cisplatin ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Drug Extravasation ,Obstetrics and Gynecology ,Alpha interferon ,medicine.disease ,Asepsis ,Surgery ,Port (medical) ,Oncology ,Medicine ,business ,Ovarian cancer ,Etoposide ,medicine.drug - Abstract
Fifty-three patients with histologically proven ovarian cancer were treated with intraperitoneally administered cisplatin or human recombinant interferon-alpha through a totally implanted peritoneal access port. A total of 281 treatment courses were given. No complications related to surgical implantation of the port were seen. Infectious complications, intra-abdominal problems or subcutaneous drug extravasation did not occur. In two patients the number of treatment courses was limited due to inflow obstruction. A totally implanted peritoneal access port proves to be a reliable route for the intraperitoneal treatment of patients with ovarian cancer. The strict aseptic technique we used contributes to its safety by preventing intra-abdominal infections.
- Published
- 1992
- Full Text
- View/download PDF